Shots:

• The P-III BLAZE-2 COVID-19 prevention trial involves assessing bamlanivimab (4-200mg) vs PBO in residents and staff at skilled nursing and assisted living facilities. The 965 &132 COVID-19 negative & positive participants were included in the analysis of 1EPS & 2EPs for assessing prevention & in exploratory analyses respectively
• The results demonstrated an 80% reduction in risk of contracting COVID-19 in residents. Results for all 2EPs also reached statistical significance in both the overall and resident populations
• Results from the exploratory analyses showed viral load is consistent with the previous studies

 ­ Ref: Lilly | Image: Eli Lilly